Pharmaceutical Chemistry Department, Faculty of Pharmacy, Hacettepe University, 06100 Sihhiye Ankara, Turkey.
Bioorg Med Chem. 2010 Apr 15;18(8):2902-11. doi: 10.1016/j.bmc.2010.03.010. Epub 2010 Mar 9.
In this study, as a continuation of our research for new (arylalkyl)imidazole anticonvulsant compounds, the design, synthesis and anticonvulsant/antimicrobial activity evaluation of a series of 2-acetylnaphthalene derivatives have been described. Molecular design of the compounds has been based on the modification of nafimidone [1-(2-naphthyl)-2-(imidazol-1-yl)ethanone], which is a representative of the (arylalkyl)imidazole anticonvulsant compounds as well as its active metabolite, nafimidone alcohol (3, 4). In general, these compounds were variously substituted at the alkyl chain between naphthalene and imidazole rings and subjected to some other modifications to evaluate additional structure-activity relationships. The anticonvulsant activity profile of those compounds was determined by maximal electroshock seizure (MES) and subcutaneous metrazol (scM) seizure tests, whereas their neurotoxicity was examined using rotarod test. All the ester derivatives of nafimidone alcohol (5a-h), which were designed as prodrugs, showed anticonvulsant activity against MES-induced seizure model. Four of the most active compounds were chosen for further anticonvulsant evaluations. Quantification of anticonvulsant protection was calculated via the ip route (ED(50) and TD(50)) for the most active candidate (5d). Observed protection in the MES model was 38.46mgkg(-1) and 123.83mgkg(-1) in mice and 20.44mgkg(-1), 56.36mgkg(-1) in rats, respectively. Most of the compounds with imidazole ring also showed antibacterial and/or antifungal activities to a certain extent in addition to their anticonvulsant activity.
在这项研究中,作为我们对新型(芳基烷基)咪唑抗惊厥化合物研究的延续,我们描述了一系列 2-乙酰萘衍生物的设计、合成和抗惊厥/抗菌活性评价。化合物的分子设计是基于对那非米酮[1-(2-萘基)-2-(咪唑-1-基)乙酮]的修饰,那非米酮是(芳基烷基)咪唑抗惊厥化合物及其活性代谢物那非米酮醇(3、4)的代表。通常,这些化合物在萘和咪唑环之间的烷基链上有不同的取代,并且进行了一些其他修饰,以评估附加的结构-活性关系。这些化合物的抗惊厥活性谱通过最大电休克发作(MES)和皮下美曲膦酯(scM)发作试验来确定,而它们的神经毒性则通过旋转棒试验来检查。所有那非米酮醇的酯衍生物(5a-h)都被设计为前药,它们对 MES 诱导的发作模型表现出抗惊厥活性。选择了四种最活跃的化合物进行进一步的抗惊厥评估。通过腹腔给药途径(ED(50)和 TD(50))对最活跃的候选物(5d)进行了抗惊厥保护的定量。在 MES 模型中观察到的保护作用在小鼠中为 38.46mgkg(-1)和 123.83mgkg(-1),在大鼠中为 20.44mgkg(-1)和 56.36mgkg(-1)。除了抗惊厥活性外,带有咪唑环的大多数化合物还具有一定程度的抗菌和/或抗真菌活性。